Nanobac Pharmaceuticals Completes Phase I Scientific Plan
Wednesday August 15, 8:00 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP
- News; "Nanobac" or "the Company") announces that it has completed
Phase I of its 2006 scientific plan advancing Nanobac's claim that
Calcifying Nano Particles (CNPs) are pathogens. Concurrent results
from scientific research conducted at the Mayo Clinic, NASA Johnson
Space Center, University of California at San Francisco, and Shantou
University Medical Center demonstrate that CNPs can induce
inflammation, calcification and thrombosis. Disease states such as
atherosclerosis (cardiovascular disease) and stone forming diseases
such as Kidney Stones, Gall Stones and Prostate Stones are all
associated with CNPs. The results of studies concerning self
replication and Koch's postulates are currently being analyzed. The
results of the studies will be detailed in subsequent releases.
Data from the completed studies confirm that Nanobac's proprietary
diagnostics specifically detect CNPs. The data further suggests that
specific drug therapies can be created to treat CNPs and that the
course of treatment can be monitored by Nanobac's proprietary
diagnostics.
"We streamlined the R & D process to specifically focus on initiatives
which we believe are the quickest path for products to market,"
commented Dr. Benedict Maniscalco, Nanobac's Co-Chairman and Chief
Medical Officer, "and we are very excited about the completed work of
our collaborative partners which allows the Company to transition to
product development."
For more information on the Company's direction please refer to the
Investor Section at nanobac.com . Further, for frequent updates on
Nanobac's progress please register as a friend of Nanobac at
nanobac.com .
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For
more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc. |
